JP6392202B2 - 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質 - Google Patents

脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質 Download PDF

Info

Publication number
JP6392202B2
JP6392202B2 JP2015500570A JP2015500570A JP6392202B2 JP 6392202 B2 JP6392202 B2 JP 6392202B2 JP 2015500570 A JP2015500570 A JP 2015500570A JP 2015500570 A JP2015500570 A JP 2015500570A JP 6392202 B2 JP6392202 B2 JP 6392202B2
Authority
JP
Japan
Prior art keywords
citrullinated
protein
seq
brain injury
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015500570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513370A (ja
JP2015513370A5 (cg-RX-API-DMAC10.html
Inventor
エイク ジェニファー イー ヴァン
エイク ジェニファー イー ヴァン
アレン デイル エヴェレット
アレン デイル エヴェレット
ツァイチェン ジン
ツァイチェン ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2015513370A publication Critical patent/JP2015513370A/ja
Publication of JP2015513370A5 publication Critical patent/JP2015513370A5/ja
Application granted granted Critical
Publication of JP6392202B2 publication Critical patent/JP6392202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
    • H01J49/0045—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction
    • H01J49/0077—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction specific reactions other than fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2015500570A 2012-03-13 2013-03-13 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質 Active JP6392202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610034P 2012-03-13 2012-03-13
US61/610,034 2012-03-13
PCT/US2013/031012 WO2013138509A1 (en) 2012-03-13 2013-03-13 Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration

Publications (3)

Publication Number Publication Date
JP2015513370A JP2015513370A (ja) 2015-05-11
JP2015513370A5 JP2015513370A5 (cg-RX-API-DMAC10.html) 2016-05-12
JP6392202B2 true JP6392202B2 (ja) 2018-09-19

Family

ID=49161784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500570A Active JP6392202B2 (ja) 2012-03-13 2013-03-13 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質

Country Status (5)

Country Link
US (4) US9709573B2 (cg-RX-API-DMAC10.html)
EP (1) EP2825893A4 (cg-RX-API-DMAC10.html)
JP (1) JP6392202B2 (cg-RX-API-DMAC10.html)
HK (1) HK1206425A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013138509A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138509A1 (en) * 2012-03-13 2013-09-19 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20160125454A1 (en) * 2014-11-04 2016-05-05 Yahoo! Inc. Systems and methods for managing advertising campaigns
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
JP6325177B2 (ja) * 2015-10-14 2018-05-16 公立大学法人横浜市立大学 腎癌薬物療法の効果判定のための血中バイオマーカー
US11143662B2 (en) 2016-06-30 2021-10-12 Brainbox Solutions, Inc. Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
EP3499230A4 (en) * 2016-08-09 2020-07-29 Otsuka Pharmaceutical Co., Ltd. Method for assisting diagnosis of alzheimer's disease using urine biomarker
KR101834724B1 (ko) 2016-08-11 2018-03-06 한림대학교 산학협력단 시트룰린화 미엘린 염기성 단백질에 대한 모노클론 항체 및 이를 이용한 신경 퇴행성 질환 진단 킷트
WO2018048884A1 (en) 2016-09-09 2018-03-15 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune gfap astrocytopathy
US20180284118A1 (en) * 2017-04-04 2018-10-04 The Johns Hopkins University Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
JP6344783B1 (ja) * 2017-06-21 2018-06-20 エフビートライアングル株式会社 ガス分析に基づく評価システム
US20210270847A1 (en) * 2018-08-17 2021-09-02 University Of Florida Research Foundation, Incorporated Protein and peptide biomarkers for traumatic injury to the central nervous system
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
CN110988207B (zh) * 2019-12-17 2021-03-23 厦门历思科技服务有限公司 基于人体摄入物质检测的监测方法
US11835519B2 (en) * 2019-12-17 2023-12-05 Euroimmun Medizinische Labordiagnostika Ag Autoantibodies to Septin-7 and diagnosis of neurological disease
EP3940383A1 (en) * 2020-07-16 2022-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the outcome of patients having acute ischemic stroke
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN120712049A (zh) 2022-12-15 2025-09-26 阿达普提克斯生物科学公司 用于分析物检测的系统和方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20030077590A1 (en) 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
WO2002024867A2 (en) 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
DE60233949D1 (de) 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US20030040660A1 (en) 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
AU2004216925B2 (en) 2003-03-07 2010-04-22 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
WO2006012351A2 (en) 2004-06-25 2006-02-02 Washington University Markers for brain damage
EP1828403B1 (en) 2004-12-04 2014-08-20 Los Alamos National Security, LLC Protein subcellular localization assays using split fluorescent proteins
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2008046509A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ltbp2 as a biomarker, therapeutic and diagnostic target
JP2008157905A (ja) 2006-12-25 2008-07-10 Hectef Standard Reference Center Foundation 添加法による生体試料中蛋白・ペプチドの定量方法
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
JP5305259B2 (ja) 2007-12-25 2013-10-02 地方独立行政法人東京都健康長寿医療センター 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
CA2715248A1 (en) 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
EP2294425B1 (en) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
EP3336551B1 (en) * 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US8119694B2 (en) 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
US9063148B2 (en) 2008-10-22 2015-06-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicince, Inc. Immunoassays for citrullinated proteins
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
JP5875514B2 (ja) 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
AU2012211328A1 (en) 2011-01-28 2013-09-19 Cyrex Laboratories, Llc Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
EP2707389B1 (en) 2011-05-12 2019-10-30 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
WO2013138509A1 (en) * 2012-03-13 2013-09-19 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2013173596A1 (en) 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
US20150141528A1 (en) 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
US10725054B2 (en) 2014-04-08 2020-07-28 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
EP3702786A1 (en) 2014-10-06 2020-09-02 Université de Genève Markers and their use in brain injury
EP3029466A1 (en) 2014-12-03 2016-06-08 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Methods for differentiating ischemic stroke from hemorrhagic stroke
CA2992343A1 (en) 2015-07-13 2017-01-19 University Of Geneva Biomarker panels for brain injury complications

Also Published As

Publication number Publication date
EP2825893A1 (en) 2015-01-21
US20150031048A1 (en) 2015-01-29
US20250085292A1 (en) 2025-03-13
JP2015513370A (ja) 2015-05-11
US12007395B2 (en) 2024-06-11
US10365288B2 (en) 2019-07-30
US20170370943A1 (en) 2017-12-28
US20190310265A1 (en) 2019-10-10
HK1206425A1 (en) 2016-01-08
US9709573B2 (en) 2017-07-18
EP2825893A4 (en) 2016-03-16
WO2013138509A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
US20250085292A1 (en) Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US11499982B2 (en) Multi-protein biomarker assay for brain injury detection and outcome
US20250044303A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
AU2019205010B2 (en) Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation
US20190234966A1 (en) Methods and compositions for tauopathy diagnosis and treatment
EP3835424A1 (en) Diagnostic drug and diagnostic method for alzheimer's disease
EP3695224A1 (en) Prognosis and progression biomarkers for chronic kidney disease
WO2018083308A1 (en) Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients
US7993868B2 (en) Saposin D and FAM3C are biomarkers for alzheimer's disease
US20110294865A1 (en) Methods of detecting a fragment of neurosecretory protein vgf for diagnosing alzheimer's disease
Kazuno et al. O‐glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer
US20250155455A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
EP4436467A1 (en) Biomarker testing for chronic persistent injury following brain trauma
WO2019012667A1 (ja) 認知機能障害疾患のバイオマーカー及び該バイオマーカーを用いる認知機能障害疾患の検出方法
JP7336097B2 (ja) 乳がんに関するペプチドマーカー
EP1907838B1 (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
JP2024117521A (ja) 膵臓がんの検出方法
JP2018163071A (ja) 関節リウマチに関するペプチドマーカー
HK40048565A (en) Diagnostic drug and diagnostic method for alzheimer's disease
HK40015171B (en) Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180822

R150 Certificate of patent or registration of utility model

Ref document number: 6392202

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250